INGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Inogen Inc (INGN) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company is undergoing a transition and has a positive analyst rating, its financial performance shows declining profitability, and technical indicators do not suggest a clear upward trend. The lack of significant trading signals and recent news further supports a cautious approach.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 59.208, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 6.504, with resistance at 6.867 and support at 6.141.
Freedom Broker initiated a Buy rating with a $12 price target, highlighting the company's transition into a broader respiratory care platform and improving operational efficiency.
Declining financial performance with a YoY drop in net income (-26.96%), EPS (-36.59%), and gross margin (-4.85%). No significant hedge fund or insider trading activity. No recent news or congress trading data.
In 2025/Q4, revenue increased by 2.05% YoY to $81.72M. However, net income dropped to -$7.13M (-26.96% YoY), EPS fell to -0.26 (-36.59% YoY), and gross margin declined to 43.12% (-4.85% YoY).
Freedom Broker initiated coverage with a Buy rating and a $12 price target, citing the company's transition into a broader respiratory care platform and improving operational efficiency.
